[Perioperative management of a patient with factor V Leiden mutation].
Although the factor V Leiden mutation had not been reported in Japan, we experienced the perioperative management of a patient with factor V Leiden mutation. A 38-year-old Caucasian woman with factor V Leiden heterozygote underwent right lobectomy for thyroid tumor under general anesthesia. The postoperative course was uneventful. Heterozygosity increases risk of venous thrombosis sevenfold. A homozygote has a 20-fold increased risk of thrombosis. Heterozygosity coupled with ingestion of oral contraceptives or pregnancy increases the risk 15-fold. Anticoagulant therapy including the use of low molecular weight heparin is considered to be appropriate for perioperative management of the patient with factor V Leiden mutation.
Kotaka
Masahito
M
Department of Anesthesiology, National Cancer Center East Hospital, Chiba 277-0882.
Kohchi
Akira
A
D000328:Adult; D000768:Anesthesia, General; D000925:Anticoagulants / Q000008:administration & dosage*; D003276:Contraceptives, Oral / Q000009:adverse effects; D005165:Factor V / Q000235:genetics*; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage*; D006579:Heterozygote; D006801:Humans; D007431:Intraoperative Complications / Q000517:prevention & control*; D009154:Mutation; D019990:Perioperative Care; D011013:Pneumonectomy; D011183:Postoperative Complications / Q000517:prevention & control*; D013964:Thyroid Neoplasms / Q000601:surgery; D020246:Venous Thrombosis / Q000517:prevention & control*
D000925:Anticoagulants; D003276:Contraceptives, Oral; D006495:Heparin, Low-Molecular-Weight; C095381:factor V Leiden; D005165:Factor V